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Abstract
During the COVID-19 pandemic, the European biobanking infrastructure is in a unique position to preserve valuable
biological material complemented with detailed data for future research purposes. Biobanks can be either integrated into
healthcare, where preservation of the biological material is a fork in clinical routine diagnostics and medical treatment
processes or they can also host prospective cohorts or material related to clinical trials. The paper discussed objectives of
BBMRI-ERIC, the European research infrastructure established to facilitate access to quality-defined biological materials
and data for research purposes, with respect to the COVID-19 crisis: (a) to collect information on available European as well
as non-European COVID-19-relevant biobanking resources in BBMRI-ERIC Directory and to facilitate access to these via
BBMRI-ERIC Negotiator platform; (b) to help harmonizing guidelines on how data and biological material is to be collected
to maximize utility for future research, including large-scale data processing in artificial intelligence, by participating in
activities such as COVID-19 Host Genetics Initiative; (c) to minimize risks for all involved parties dealing with (potentially)
infectious material by developing recommendations and guidelines; (d) to provide a European-wide platform of exchange in
relation to ethical, legal, and societal issues (ELSI) specific to the collection of biological material and data during the
COVID-19 pandemic.
Introduction
During the COVID-19 pandemic, the European biobank-
ing infrastructure is in a unique position to preserve
valuable biological material complemented with detailed
data for future research purposes. Many biobanks are
integrated into healthcare, where preservation of the
biological material is a fork in clinical routine diagnostics
and medical treatment processes; these are called clinical
biobanks or clinical collections. Biobanks can also host
prospective cohorts or material related to clinical trials.
Amount and structure of collected data in clinical col-
lections is determined by the specifics of the particular
healthcare systems—typically based on the hospital
information systems—for potentially large numbers of
patients, especially when these are handled by the
healthcare during pandemics. Prospective cohorts and
clinical trials feature more structured data models and
large amounts of data collected in controlled conditions,
but at the cost of having a substantially lower number of
patients.
Owing to the pandemic, we can observe an unprece-
dented stressing of the healthcare systems, which requires
that, more than ever, sample and data collection happens as
unobtrusively as possible for the primary care. Data col-
lection processes, while they are dependent on local/
national settings, should result in well-defined structured
data suitable for multisite national and international data
integration and large-scale machine analyses, following
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FAIR [1] and FAIR-Health [2] principles (extensions of
FAIR related to quality and privacy). In addition, bio-
banking material with (possibly) infectious viral material
should be prepared in relatively sparse BSL-3 certified
laboratories; alternatively, material needs to be deactivated
to enable processing in much more abundant BSL-2
laboratories.1
Amidst the COVID-19 crisis, the objectives of
BBMRI-ERIC, the European research infrastructure
established to facilitate access to quality-defined biologi-
cal materials and data for research purposes, are clear: (a)
to collect information on available European as well as
non-European COVID-19-relevant biobanking resources
and to facilitate access to these; (b) to help harmonizing
guidelines on how data and biological material is to be
collected to maximize utility for future research, including
large-scale data processing in artificial intelligence; (c) to
minimize risks for all involved parties dealing with
(potentially) infectious material; (d) to provide a
European-wide platform of exchange in relation to ethical,
legal, and societal issues (ELSI) specific to the collection
of biological material and data during the COVID-19
pandemic. Achieving these objectives will substantially
support further research into COVID-19, and hence it is
key to connect early and effectively in a multidisciplinary
manner with other key facilitators of medical research,
such as the research infrastructures ECRIN (multinational
clinical trials) and EATRIS (translational medicine)2 or
the broader community of research infrastructures, which
already mobilized considerable resources across all sci-
entific clusters.3
COVID-19 resources in the BBMRI-ERIC
network
In order to ensure findability of biobanking resources,
BBMRI-ERIC operates two main services: (1) the BBMRI-
ERIC Directory,4 which works on aggregate metadata
descriptors of biobanks and their collections, and (2) the
BBMRI-ERIC Locator,5 which works as a federated search
tool allowing to query individual-level data at the sites of
origin while returning aggregated results.
To date, the Directory has been at the center of BBMRI-
ERIC’s initial COVID-19-related activities. The aggregated
nature of the underlying data allows for a low entry bar to
register resources and thus any COVID-19-related resources
could be included easily regardless of the country of origin.
The Directory data model is based on MIABIS Core 2.0 [3]
with the concept of biobanks (institutions) and collections
(of data and samples) and it has been extended with
COVID-relevant attributes as shown in Table 1. Existing
collections of COVID-positive samples will be marked with
respective ICD-10 codes and COVID-specific collection
attributes. Prospective collections can be advertised as
empty collections with COVID-specific collection attributes
defining what data can be collected. The metadata
descriptors were initially collected by BBMRI-ERIC’s
National Nodes (represented throughout 21 member
states),6 and now the Directory is ready to accept updates
via National Nodes or via the BBMRI-ERIC Helpdesk.7
The Directory data model is being continuously optimized
based on the feedback from and needs of the research and
biobanking communities. The model is also being deployed
in national nodes to collect the relevant information, using
the underlying MOLGENIS platform [4] to quickly
Table 1 Overview of COVID-specific attributes added to BBMRI-ERIC Directory.
Attributes added on the biobank level Attributes added on the collection level
Biobank providing services relevant to COVID-19:
•Member COVID-19 network
Availability of the services provided by the biobank:
•Antibody development
• Proteomics studies including protein engineering and protein interactions
• Screening tools for searching virus proteases inhibitors
•Animal testing facility
•Ability to set up prospective collections




• Laboratories doing PCR-based diagnosis
Relevant diagnoses:
•U07.1—laboratory-confirmed COVID-19 diagnosis
•U07.2—suspect or probable COVID-19 diagnosis
Availability of relevant data and products:
•Data on clinical symptoms
•Data on disease duration and disease outcome
•Antibodies titer (IgM and IgG)
•CT imaging of lungs, alternatively Xray
•Blood count and other lab results especially at the moment of
hospital admission,
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configure locally needed extensions. In order to maximize
findability, the Directory also serves as a data source for
aggregation services such as FAIRSharing.org and Google
dataset search.
Effective access to the biobanking resources, as adver-
tised in the Directory, is possible via the BBMRI-ERIC
Negotiator8. After a researcher identifies relevant biobanks
in the Directory, she can use the “Request access” func-
tionality and follow the access procedure; this involves
authenticating using BBMRI-ERIC Authentication and
Authorization Infrastructure, describing her project and
specific request details and information on ethics review if
available. Once this initial information is provided, the
identified biobanks are notified and the access negotiation
starts. Using the Negotiator, the researcher can effectively
negotiate with several biobanks at once and insufficiently
specified requests can be quickly clarified.
In the near future, the federated search in the BBMRI-
ERIC Locator will be extended with the COVID-specific
attributes; the extension depends on an initial consensus of
the international communities on common data models
describing patient-level information. The BBMRI-ERIC
community therefore participates in the global ‘COVID-19
Host Genetics Initiative’9 and actively monitors other
initiatives such as OHDSI COVID-19 work.10 Outcomes of
these initiatives will need to be practically assessed in order
to ultimately verify what information can be effectively
made available for querying in practice of clinical bio-
banking in different countries.
Development of quality and safety guidance
Collection of quality biological material from patients with
suspected and confirmed COVID-19 might be a challenge
due to infection risk related to the procedures performed on
different types of biospecimen. In most cases, samples
collected from upper respiratory tract (swabs, sputum,
bronchoalveolar lavage) seem to be associated with the
highest risk due to the content of active virus when com-
pared with the whole blood and blood derivatives [5]. In
addition, assessment of the virus load in such samples
collected from asymptomatic individuals and those who
show typical COVID-19 symptoms, showed no statistically
significant difference with the highest viral load at the
presentation [6]. Stool samples, collected by many bio-
banks, are also amongst highly infectious material in con-
trast to serum and plasma [5, 7]. Safety measures for
fractionation and storage of urine samples should be also
performed due to inconsistent data on viral load, indicating
that urine might be potentially infectious [8] but this stays in
contrast with other reports [5]. While the most current
publications are a valuable source of the latest knowledge,
they might also provide conflicting advice and limited data.
Laboratories performing work on biological specimens
should thus strictly follow well-established guidelines such
as those published by WHO,11 ECDC,12 as well as local
epidemiological surveillance. According to these recom-
mendations the individual risk assessment is becoming a
key step before starting the work with SARS-CoV-2 sus-
pected samples in order to decide whether sample proces-
sing requires BSL-3 or BSL-2 standard. High virulence of
SARS-CoV-2 and the lack of suitable equipment in many
facilities, indicates the possibility of taking steps that
minimize contact with potentially infectious material. It is
essential to establish the flow of biological material between
clinical laboratories and biobanks that will perform the
minimum steps associated with the processing of biological
material and will be responsible for its safe storage until
release—such as guidelines established by Czech National
Node of BBMRI-ERIC [9]. In response to the needs of the
biobanking community, BBMRI-ERIC organized a series of
online meetings with clinical and laboratory experts and
provided the access to guidelines enabling the preparation
of biobanks for working with samples obtained from
COVID-19 patients13. International standards on risk man-
agement and safety, such as ISO 20387:2018, 31000:2018,
31004:2013, and 15190:2020, should be also followed
when applicable.
Appropriate ethical and legal requirements
As regards to ethical requirements and biobanking, the same
guidelines persist also in the context of COVID-19,
allowing for practical adjustments in emergency situa-
tions.14,15,16 Oversight in the midst of the pandemic, typi-
cally the responsibility of the local ethics committee, has
been frequently adjusted to meet the urgency of COVID-19
by ensuring fast response such as 48 h.
8 https://negotiator.bbmri-eric.eu/







normativo/ (for an excellent overview of ELSI guidelines, tailored
for the situation in Italy)
15 https://unesdoc.unesco.org/ark:/48223/pf0000146180 (esp Article
8. Respect for human vulnerability and personal integrity).
16 https://www.wma.net/policies-post/wma-declaration-of-helsinki-
ethical-principles-for-medical-research-involving-human-subjects/
(esp principle 30, which is concerned with research participants that
are mentally or physically unable to consent).
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In relation to data processing during an emergency
situation, the GDPR explicitly enables competent public
health authorities to lawfully process personal data for
reasons of substantial public interest in the area of public
health conditionally without informed consent.17 In a gui-
dance document on the management of clinical trials during
the COVID-19 pandemic,18 for instance, it is further spe-
cified to obtain the consent from the patient (or her/his legal
representative) at a later stage. This recommendation
applies to “acute life-threatening situations”, where it is not
possible to obtain consent in advance and only when
allowed within national legislation. In the context of bio-
banks, broad consent can be used if it has already been
integrated prior to the emergency situation in the clinical
admission processes.
Conclusion
By integrating the COVID-19 resources in the Directory,
BBMRI-ERIC aims to contribute its unique European
research infrastructure, with its National Nodes and colla-
borators not only the preservation of valuable biological
material complemented with detailed data, but also to ensure
timely knowledge exchange on quality management and
guidance on safety and ethical and legal requirements and
their practical application. Where appropriate in collaboration
with other organizations or societies, BBMRI-ERIC will
continue to organize and disseminate responses to the needs
of the community, including webinars or FAQs.
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